S&P Futures
4,087.75 +7.75 (+0.19%) Dow Futures
33,132.00 +88.00 (+0.27%) Nasdaq Futures
13,076.00 -6.00 (-0.05%) Russell 2000 Futures
1,786.30 +6.20 (+0.35%) Crude Oil
74.78 +0.41 (+0.55%) Gold
1,997.70 0.00 (0.00%)
Brainstorm Cell Therapeutics Inc. (BCLI)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 2.4400 |
| Open | 2.4200 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 900 |
| Day's Range | 2.0250 - 2.6000 |
| 52 Week Range | 1.0900 - 4.7000 |
| Volume | |
| Avg. Volume | 321,196 |
| Market Cap | 121.144M |
| Beta (5Y Monthly) | -0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7000 |
| Earnings Date | May 15, 2023 - May 19, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.50 |
- PR Newswire
BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022 and provided a corporate update.
- Zacks Small Cap Research
BCLI: FDA Grants Adcom for NurOwn®…
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update AdCom Granted for NurOwn® On March 27, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has granted an Advisory Committee (AdCom) meeting to discuss the company’s Biologics License Application (BLA) for NurOwn® for the treatment of amyotrophic lateral
- PR Newswire
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee Meeting ('ADCOM') to discuss the company's Biologics License Application (BLA) for NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). Given the goal to proceed to an ADCOM as expeditiously as possible, BrainStorm requested that the Center for Biologics E
